Fig. 1: Vaccination with glioma GL261 cells pulsed with PS-PDT in the subcutaneous prophylactic vaccination mouse model. | Cell Death & Disease

Fig. 1: Vaccination with glioma GL261 cells pulsed with PS-PDT in the subcutaneous prophylactic vaccination mouse model.

From: DC vaccines loaded with glioma cells killed by photodynamic therapy induce Th17 anti-tumor immunity and provide a four-gene signature for glioma prognosis

Fig. 1: Vaccination with glioma GL261 cells pulsed with PS-PDT in the subcutaneous prophylactic vaccination mouse model.The alt text for this image may have been generated using AI.

A Prophylactic vaccination of mice was performed by injecting them in the left flank on days 0 and 7 with dying/dead GL261 cells treated with three F/T cycles, 2.0 µM MTX, or PS-PDT, or by injecting them with PBS (negative control). Seven days later, the mice were challenged with viable GL261 cells in the right flank. B Tumor appearance (% survival) and growth C at the challenge site in mice subjected to vaccination and challenge with viable GL261 cells; n = 5–6 per group. *Statistically significant difference from the PBS group, (p < 0.05); #statistically significant difference from the F/T group, (p < 0.05), Wilcoxon test.

Back to article page